Call Us: 1.800.873.5297

By

Xarelto Expanded Use Denied Again by FDA

According to Reuters, the FDA once again declined to approve wider uses of the prescription drug Xarelto® (Rivaroxaban) late last month. Currently, the drug’s biggest approved use is to prevent blood clots and strokes in patients with an irregular heartbeat called atrial fibrillation. Recently, the drug’s co-marketers—Bayer AG and Johnson & Johnson—tried to expand the drug’s […]

By

Alere INRatio® Test Strips, Monitor System Recalled

If you have been taking a blood-thinning drug (such as warfarin/Coumadin) or have been receiving heparin injections, you should be aware of an urgent recall of INRatio® PT/INR test strips and monitors. These products are used to test a patient’s INR (international normalized ratio) when taking warfarin and other anticoagulation medications. The goal with warfarin […]

By

Xarelto® Lawsuit Update: Roger Denton Appears on Live Radio Show to Discuss Dangers of Xarelto®

On October 10, 2014, Roger Denton of Schlichter, Bogard & Denton, LLP appeared as a guest on the “Majority Report with Sam Seder” live radio show to discuss Xarelto®, a prescription anticoagulant that is the subject of recent lawsuits in the United States. Click here to listen to the segment. Denton explained that Xarelto® was […]

By

Pradaxa® MDL 2385 Update: Court Orders Establishment of Qualified Settlement Fund

The Honorable Judge David Herndon, who is overseeing the Pradaxa® Multidistrict Litigation, has ordered the establishment of a “qualified settlement fund” and appointed an administrator of the settlement fund. (CMO 82, In re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation, Case No. 12-md-2385, S.D. Ill.) Now that a qualified settlement fund has been established and an […]

By

Xarelto® Lawsuit Update: New Study Finds Bleeding Difficult to Stop for Some Anticoagulants, Including Xarelto®

A new study published in the August issue of the Journal of Neurosurgery found that internal bleeding associated with certain anticoagulants – including Xarelto® – is more difficult to stop in comparison to other blood thinning medications. The study discussed new guidelines on how to treat uncontrolled bleeding in the brain and pointed out that […]

By

FDA Warns of Low-Dose Use of Aspirin

The U.S. Food and Drug Administration (FDA) has announced that low-dose aspirin should not be marketed to prevent a first heart attack or stroke in patients with no history of cardiovascular disease. The alert was issued after Bayer Corporation, the manufacturer of the most widely sold brand of aspirin, filed a petition with the FDA […]

By

FDA Issues New Safety Announcement: Increased Risk of Major GI Bleeding with Pradaxa Compared to Warfarin

On May 13, 2014, the FDA issued a Safety Announcement for Pradaxa regarding a recent study finding a higher risk of gastrointestinal (GI) bleeding with Pradaxa compared to warfarin. This information is in follow-up to the FDA’s Drug Safety Communication previously issued on November 2, 2012 regarding the risk of serious bleeding events with Pradaxa. […]

By

Pradaxa Lawsuit Update (MDL 2385): News Articles Report BI Altered Research Paper it Feared Would Harm Sales

What if a pharmaceutical company knew that its drug required frequent testing to reduce the potential danger to patients, yet hid that information? According to two recent news articles, the manufacturer of the anticoagulant drug Pradaxa may have done just that. The problem may start with “the fact that much of the research on drugs […]

By

Pradaxa Lawsuit Update (MDL 2385): Internal Company Documents Recently Unsealed in MDL, as Reported by The New York Times

The New York Times reports that numerous documents have been made public in the Pradaxa® Multidistrict Litigation entitled In re: Pradaxa® (Dabigatran Etexilate) Products Liability Litigation (MDL 2385, Case No. 12-md-2385) pending in the United States District Court for the Southern District of Illinois. The New York Times provides: “Many of the documents released by […]

By

Over 1,400 Lawsuits Pending in Federal Court Against Manufacturers of Pradaxa®

Since August, 79 lawsuits have been filed in federal court against the manufacturers of Pradaxa®. These lawsuits have been added to the Multidistrict Litigation In re: Pradaxa® (Dabigatran Etexilate) Products Liability Litigation (MDL 2385), which is currently pending in the United States District Court for the Southern District of Illinois before the Honorable Chief Judge […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.